Affected by the third quarterly report disclosure window, the company received institutional research has been reduced. Data show that in October, the agency researched 190 companies, only one-third of the same period last month; 116 companies were more than 10 (including) organizations group research, is less than half of the same period last month. From the industry point of view, pharmaceutical and biological stocks are the most attention of the organization.
October institutional research 190 shares
Just the end of the trading day in October is listed companies in 2020 the third quarter of the disclosure of the month, the impact of which, the acceptance of institutional research companies significantly reduced. According to flush iFinD data statistics, in October to accept institutional research companies only 190, just September the same period 545 34.86%. Among them, 116 companies were more than 10 (including) organizations group research, but also just the same period of 237 48.95%.
Among them, Gore shares (002241), Hikvision (002415), Quanta (002410), China test (300012), Changchun High-tech (000661), new industry (300832), China Science and Technology Chuangda (300496), Ganyuan Foods (002991), Miyabeke (300188), Huayu software (300271), Desai Xixi software (300271), and the company's software (002991), and the company's software (002991), and the company's software (002991). 300271), Desai Xiwei (002920), Josun Micro (300782), Haida Group (002311), light Wei compound material (300699), Xingyuan material (300568), I Wu biological (300357) and other 16 companies accepted more than 100 organizations research.
The most popular institutional attention is Geer shares. Data show that in October, the company received a total of 330 institutions, including 110 public funds, 37 brokers, 33 sunshine private equity, 39 overseas institutions, 23 insurance companies and other packet group research. Research, Geer shares on its main business segments of the future trend are to maintain optimistic expectations. For example, in the components business, in addition to the traditional precision components business, the company is also actively expanding related parts business, including acoustic-related haptics, wireless charging and other components business, SiP products business on behalf of the future direction, as well as optical, precision structural components.
Behind the many institutions stepping through the threshold is Geer's third quarterly report greatly exceeded expectations. The three quarterly report shows that Geer achieved revenue of 34.73 billion yuan in the first three quarters, an increase of 43.9% year-on-year; mother net profit of 2.016 billion yuan, an increase of 104.71% year-on-year; of which, the company's third quarter realized mother net profit of 1.236 billion yuan, an increase of 167.92% year-on-year. In addition, Geer expects 2020 net profit of about 2.753 billion yuan to 2.881 billion yuan, an increase of 115.0% to 125.0% year-on-year. The performance growth is mainly due to the company's smart wireless headphones (TWS headphones), precision components and virtual reality and other related products sales revenue growth.
In addition, Aibo Medical (688050), IZP (300415), Honglu Steel Structure (002541), KUDA Xunfei (002230), Perrier (603605), Shuangta Foods (002481), Tenci Materials (002709), Stable Medical (300888), Xinjianneng (605111), Jinbo Stock ( 688598), East China Pharmaceutical (000963), Shangpin House with (300616), Yuxin Technology (300674), the source of vision shares (002841), Pro Pharmaceuticals (000739), Zhengbang Technology (002157) and other 23 companies have also accepted more than 50 institutional research.
From the institutional research number, Hoyun technology for the most intensive institutional research company. Data show that the cloud technology in October to accept 6 batches of institutional research. Yonggao shares (002641) and Hanwang Technology (002362) are 4 times to be institutional research, tied for second. In addition, Desai Xihui, Honglu steel structure (002541), Jinbo shares (688598), Chujiang new material (002171), in the days of fine decorating (002989), Han Zhongjingji (002158), Feng Shang culture (300860), deep science and technology (000021), seagulls live in the work of the 9 companies to accept more than 3 times research institutions.
Pharmaceutical and biological stocks are the most concerned
From the research company belongs to the industry point of view, in October, the agency research listed companies are mainly concentrated in the pharmaceutical and biological (24), electronics (21), computers (17), machinery and equipment (16), chemical industry (14), electrical equipment (13) food and drink ( 11), light manufacturing (10) and other 8 industries. Obviously, pharmaceutical and biological research in October institutions are the most popular.
Han Guangzhe, manager of the Golden Eagle Medical Health Industry Stock Fund, said the A-share market pharmaceutical industry companies after short-term adjustments, partially digested the high valuation pressure, will adhere to the bottom-up tracking of key pharmaceutical companies. Cheese fund manager Zhuang Hongdong said that at the beginning of the year, the valuation of pharmaceutical stocks is not high, performance certainty is stronger, superimposed on the catalyst of the epidemic, there was a wave of larger market. But the epidemic is also just a quarter or two of the performance of the relevant companies contribute more, not a continuing contribution.
In the three-quarter report, Harvest RXI three-year closed operation mixed fund manager Hong Liu said, reduced the proportion of some of the cumulative increase in the allocation of pharmaceutical listed companies is too high. Rongtong Health Industry Flexible Configuration three quarterly report shows that the fund manager selected track and growth of better and relatively low valuation of individual stocks to focus on the allocation, reduce the allocation of health insurance fee control damage to the larger related subjects, medium-term stock holding mentality from the waiting, with time for space and timely adjustment of the portfolio structure.
But there are also fund managers in the third quarter to choose to increase the position of the pharmaceutical stocks, ICBC Credit Suisse Medicine Health Industry Stocks Fund Manager said in the third quarterly report, the third quarter of the adjustment of the pharmaceutical stocks, the fund seized the opportunity to moderately increase the position. In terms of structure, we have maintained core positions in innovative drugs, innovative medical devices, CDMOs and other long-term bullish areas, and reduced positions in epidemic-benefiting subfields.
The manager of ChinaAMC Healthcare Mixed Fund believes that pharmaceuticals is an industry worth investing in for the long term, and that China's aging population and the development of its economic level constitute a long-term support for the pharmaceutical industry from the demand side to the payment side. Therefore, the process of constructing the portfolio is also based on the long term, selecting companies with space, business model barriers or competitive advantages to invest in, in an effort to bring stable returns to investors. In the selection of pharmaceutical sub-industry, portfolio construction will combine long-term space and prosperity, taking into account valuation and other factors, try to choose a relatively decentralized sub-industry, to avoid exposure to excessive risk in a single driving factor.
Hurong Quan, manager of the Guolian Ruiyi Growth Fund, said that from a long-term perspective, the pharmaceutical industry has a lot of room for growth in the future, the core of which is that the penetration rate of individual medicines and devices is still very low, superimposed on the continuous improvement of the innovation capacity of the enterprise, and more demand will be created one after another. Currently, the market is already gradually reflecting this future long-term trend. The valuation of core stocks is generally high, and investment in the pharmaceutical industry should pay more attention to the industry track and the certainty of growth, and the holding cycle may be longer.
Companies surveyed by at least 30 organizations in October
This article was originally published on wealthpower.com